Search

Your search keyword '"Ruvolo, Vivian R."' showing total 227 results

Search Constraints

Start Over You searched for: Author "Ruvolo, Vivian R." Remove constraint Author: "Ruvolo, Vivian R."
227 results on '"Ruvolo, Vivian R."'

Search Results

3. Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial

4. Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

5. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

7. Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia

8. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias

11. Supplementary Tables 1-9 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

12. Abstract A31: C-MYC Targeting by Degradation: Novel Dual c-MYC/GSPT1 Degrader GT19715 Induces TP53-independent Cell Death in MYC-amplified Acute Myeloid Leukemia and Lymphomas

13. Data from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

14. Supplementary Figures 1-8 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

16. Data from Focal Adhesion Kinase as a Potential Target in AML and MDS

17. Supplementary Tables 1 and 2 and Supplementary Figures 1 through 7 from Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells

18. Supplementary Fig. S1 from Focal Adhesion Kinase as a Potential Target in AML and MDS

19. Supplemental Figure 1 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

20. Supplemental Figure 3 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

21. Supplemental Figure 2 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

22. Supplemental Figure 4 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

23. Supplemental Figure 5 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

24. Supplementary Tables 1 and 2 and Supplementary Figures 1 through 5 from The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations

26. Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

30. Poster: AML-147 C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill In Vitro and In Vivo in Acute Myeloid Leukemia and Lymphomas

31. C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill in vitro and in vivo in Acute Myeloid Leukemia and Lymphomas

32. Enhanced TP53 Reactivation Disrupts MYC Transcriptional Program and Overcomes Venetoclax Resistance in Acute Myeloid Leukemias

33. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia

36. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

38. Abstract 2720: Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality

39. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

40. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality

41. A miR-155/TP53 regulatory feedback loop involved in resistance to therapy in lung cancer and leukemia

42. Role of MSC-derived galectin 3 in the AML microenvironment

43. Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival

44. MCL-1 Up-Regulation through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML Models

45. Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms

46. Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models

47. Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells

48. Focal Adhesion Kinase as a Potential Target in AML and MDS

49. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Catalog

Books, media, physical & digital resources